Sun Pharma had received approval for this drug in August 2016 when the addressable size of the market was $1.2bn.
Lupin had a FTF of this drug and in February 2016, it launched generic of version of this drug. Teva also launched its own copycat of this drug in May 2017.
As per IQVIA, the current addressable market size for this drug is ~$443mn for the 12 months ending April 2018.
Sun Pharmaceuticals Industries Ltd is currently trading at Rs557.70 down by Rs4.8 or 0.85% from its previous closing of Rs562.50 on the BSE.